MGX
Metagenomi Therapeutics, Inc. · Healthcare · Market cap $31.3M
Insiders bought $18K net in the last 90 days ·3 sellers, 1 buyer· latest Form 4 filed Sep 11, 2026
Insider Buying
$23K
reported purchases (SEC code P)
Insider Selling
$44K
reported sales (SEC code S)
Unique Insiders
5
in the rolling window
Latest filing
Sep 11, 2026
Reid Laurence
Metagenomi Therapeutics, Inc. (MGX) has 21 SEC Form 4 filings (27 transaction rows) in the rolling window, disclosed by 5 distinct insiders. Most recent filing: Sep 11, 2026.
Inside the rolling window, 5 insiders at Metagenomi Therapeutics, Inc. reported 1 open-market purchase totaling $23K and 17 open-market sales totaling $44K. The most active filer is See Remarks Wein Matthew with 5 filings. The most recent open-market filing is a purchase of 20,000 shares by Director Reid Laurence, dated Sep 9, 2026, worth $23K.
- Industry:Biotechnology
- CEO:Jian Irish
- Employees:118
- HQ:Emeryville, CA, US
- IPO:2024-02-09
| Source | |||||||
|---|---|---|---|---|---|---|---|
Reid LaurenceFirst filing | Director | Purchase | 20,000 | $23K | Sep 11 | -28.5% | SEC ↗ |
Wein MatthewFirst in 3 months | See Remarks | Sale | 358 | $415 | Sep 10 | -28.5% | SEC ↗ |
Irish JianFirst in 3 months | See Remarks | Sale | 2,140 | $2K | Sep 10 | -28.5% | SEC ↗ |
Wapnick PamelaFirst in 3 months | Chief Financial Officer | Sale | 1,911 | $2K | Sep 10 | -28.5% | SEC ↗ |
Wapnick PamelaFirst in 3 months | Chief Financial Officer | Sale | 2,884 | $4K | Jun 10 | -32.6% | SEC ↗ |
Irish JianFirst in 3 months | See Remarks | Sale | 3,737 | $5K | Jun 10 | -32.6% | SEC ↗ |
Wein MatthewFirst in 3 months | See Remarks | Sale | 558 | $725 | Jun 10 | -32.6% | SEC ↗ |
Irish JianFirst in 3 months | Chief Executive Officer | Sale | 1,607 | $3K | Mar 9 | -48.2% | SEC ↗ |
Wapnick PamelaFirst in 3 months | Chief Financial Officer | Sale | 1,581 | $3K | Mar 9 | -48.2% | SEC ↗ |
Wein MatthewFirst in 3 months | See Remarks | Sale | 482 | $771 | Mar 9 | — | SEC ↗ |
| Chief Financial Officer | Sale | 1,576 | $3K | Dec 8 | — | SEC ↗ | |
| Chief Executive Officer | Sale | 1,602 | $3K | Dec 8 | — | SEC ↗ | |
| Director | Sale | 3,830 | $7K | Dec 8 | — | SEC ↗ | |
| See Remarks | Sale | 199 | $353 | Dec 8 | — | SEC ↗ | |
Irish JianFirst filing | Chief Executive Officer | Sale | 1,602 | $3K | Dec 1 | — | SEC ↗ |
Wein MatthewFirst filing | See Remarks | Sale | 199 | $360 | Dec 1 | — | SEC ↗ |
Wapnick PamelaFirst filing | Chief Financial Officer | Sale | 1,576 | $3K | Dec 1 | — | SEC ↗ |
Thomas Brian C.First filing | Director | Sale | 2,701 | $5K | Dec 1 | — | SEC ↗ |
Frequently asked questions
How many SEC Form 4 insider filings does MGX have?
Metagenomi Therapeutics, Inc. (MGX) has 21 SEC Form 4 filings (27 transaction rows) in the rolling 365-day window, disclosed by 5 distinct insiders. Most recent filing: Sep 11, 2026.
When was the most recent SEC Form 4 filing for MGX?
The most recent Form 4 filing for MGX on Tracefour is dated Sep 11, 2026.
Who is the most active insider at MGX?
The most active SEC Form 4 filer at MGX in the rolling window is See Remarks Wein Matthew, with 5 filings.
What is the net insider flow at MGX over the last 6 months?
Over the trailing 180 days, insiders at MGX have net bought $9K based on SEC Form 4 disclosures.
What is the total insider buy and sell value at MGX in the current window?
Inside the rolling window, insiders at MGX bought $23K and sold $44K based on SEC Form 4 filings.
Can I get alerts for MGX insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Metagenomi Therapeutics, Inc. (MGX). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Metagenomi Therapeutics, Inc. is in the Healthcare sector.